SWCRF collaborator Paul B. Fisher, MPh, PhD elected to the 2017 Class of National Academy of Inventors Fellows 

 

Paul B. Fisher, MPh, PhD

The Samuel Waxman Cancer Research Foundation (SWCRF) congratulates its longtime scientific collaborator Paul B. Fisher, MPh, PhD, who is among 155 renowned academic inventors elected in December to the 2017 class of Fellows of the National Academy of Inventors (NAI), a nonprofit organization that enhances the visibility of academic technology and innovation. The 2017 Fellows are named inventors on nearly 6,000 issued U.S. patents, bringing the collective patents held by all NAI Fellows to more than 32,000 issued U.S. patents.

Dr. Fisher is an inventor on 55 issued US Patents and is an author or co-author on approximately 600 peer-reviewed publications and reviews in the areas of cancer gene discovery, novel approaches for gene identification/cloning, strategies for imaging primary cancers and metastases, discovery of small molecule inhibitors of cancer invasion and metastasis, and creation of unique immunotherapeutic Cancer Terminator Viruses. He was also chosen as Virginia Outstanding Scientist in 2014. While at Columbia University in NY, his ground-breaking discoveries led to the formation of the functional genomics company GenQuest, Inc., which merged with Corixa Corporation, traded on NASDAQ and was acquired by GlaxoSmithKline. At Virginia Commonwealth University, School of Medicine in Richmond, VA, Fisher co-founded Cancer Targeting Systems (CTS) with Dr. Martin A. Pomper of Johns Hopkins Medical Center and recently (2017) co-founded InVaMet Therapeutics, Inc. (IVMT) and InterLeukin Combinatorial Therapies, Inc. (ILCT) with Dr. Webster K. Cavenee of the Ludwig Institute for Cancer Research, UCSD.

Election to NAI Fellow status is the highest professional accolade bestowed to academic inventors who have demonstrated a prolific spirit of innovation in creating or facilitating outstanding inventions that have made a tangible impact on quality of life, economic development, and welfare of society. NAI Fellows have generated more than 9,400 licensed technologies and companies and created more than 1.3 million jobs, with over $137 billion in revenue generated based on their discoveries. 

Dr. Fisher, Professor and Chairman, Director of the Department of Human and Molecular Genetics at the VCU Institute of Molecular Medicine at Virginia Commonwealth University, and holds the Thelma Newmeyer Corman Chair in Cancer Research in the Massey Cancer Center, will be inducted into the 2017 class at the Seventh Annual NAI Conference on April 5 in Washington, DC.  He joins SWCRF grantee Ronald Evans, PhD, and former SWCRF Scientific Advisory Board member Riccardo Dalla-Favera, MD, as a member of the NAI Fellows. 

Andrew H. Hirshfeld, U.S. Patent and Trademark Office (USPTO) Commissioner for Patents, will provide the keynote address for the induction ceremony. 

“This honor is further evidence of the leading-edge science practiced by the collaborators within the SWCRF Institute Without Walls,” said Dr. Samuel Waxman, founder and CEO of the Samuel Waxman Cancer Research Foundation. “Our past and present collaborators make headlines with their work every day and are leaving an indelible impact on the world of science. We congratulate Paul Fisher on this richly deserved accolade.” 

Those elected to the rank of NAI Fellow were nominated by their peers for outstanding contributions in areas such as patents and licensing, innovative discovery and technology, significant impact on society, and support and enhancement of innovation